Liminatus Pharma, Class Stock Performance
| LIMN Stock | 0.65 0 0.46% |
The company secures a Beta (Market Risk) of 1.39, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Liminatus Pharma, will likely underperform. At this point, Liminatus Pharma, Class has a negative expected return of -1.22%. Please make sure to verify Liminatus Pharma,'s potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Liminatus Pharma, Class performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Liminatus Pharma, Class has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's primary indicators remain very healthy which may send shares a bit higher in January 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
1 | LIMN 10Q Equity Conversions, 7.8M Underwriting Liability Noted - Stock Titan | 10/03/2025 |
2 | What risks investors should watch in Liminatus Pharma Inc. Equity Warrant stock - Weekly Volume Report Safe Capital Growth Trade Ideas - newser.com | 10/21/2025 |
3 | Liminatus Pharma, Inc. Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation | 10/30/2025 |
4 | Signal strength of Liminatus Pharma Inc. stock in tech scanners - 2025 Major Catalysts Real-Time Stock Entry Alerts - newser.com | 11/12/2025 |
5 | Liminatus Pharma, Inc. Class A Common Stock -29.6 percent in Normal Trading Significant Drop Amid Routine Trading - Stocks Telegraph | 11/21/2025 |
6 | Financial Survey Liminatus Pharma Inhibikase Therapeutics | 12/04/2025 |
| Begin Period Cash Flow | 156.4 K | |
| Total Cashflows From Investing Activities | 2 M | |
| Free Cash Flow | -3.1 M |
Liminatus | Build AI portfolio with Liminatus Stock |
Liminatus Pharma, Relative Risk vs. Return Landscape
If you would invest 167.00 in Liminatus Pharma, Class on September 30, 2025 and sell it today you would lose (102.30) from holding Liminatus Pharma, Class or give up 61.26% of portfolio value over 90 days. Liminatus Pharma, Class is currently does not generate positive expected returns and assumes 6.9185% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Liminatus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Liminatus Pharma, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Liminatus Pharma,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Liminatus Pharma, Class, and traders can use it to determine the average amount a Liminatus Pharma,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1759
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LIMN |
Based on monthly moving average Liminatus Pharma, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Liminatus Pharma, by adding Liminatus Pharma, to a well-diversified portfolio.
Liminatus Pharma, Fundamentals Growth
Liminatus Stock prices reflect investors' perceptions of the future prospects and financial health of Liminatus Pharma,, and Liminatus Pharma, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Liminatus Stock performance.
| Current Valuation | 160.23 M | ||||
| Shares Outstanding | 26.01 M | ||||
| EBITDA | (2.75 M) | ||||
| Net Income | (2.9 M) | ||||
| Total Debt | 5.12 M | ||||
| Cash Flow From Operations | (3.11 M) | ||||
| Earnings Per Share | (0.16) X | ||||
| Market Capitalization | 145.16 M | ||||
| Total Asset | 2.83 M | ||||
| Retained Earnings | (17.52 M) | ||||
| Working Capital | (15.79 M) | ||||
About Liminatus Pharma, Performance
By examining Liminatus Pharma,'s fundamental ratios, stakeholders can obtain critical insights into Liminatus Pharma,'s financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Liminatus Pharma, is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.03) | (0.98) | |
| Return On Capital Employed | 0.50 | 0.84 | |
| Return On Assets | (1.03) | (0.98) | |
| Return On Equity | 0.18 | 0.19 |
Things to note about Liminatus Pharma, Class performance evaluation
Checking the ongoing alerts about Liminatus Pharma, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Liminatus Pharma, Class help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Liminatus Pharma, generated a negative expected return over the last 90 days | |
| Liminatus Pharma, has high historical volatility and very poor performance | |
| Liminatus Pharma, has some characteristics of a very speculative penny stock | |
| Liminatus Pharma, has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (2.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Liminatus Pharma, generates negative cash flow from operations | |
| Liminatus Pharma, has a poor financial position based on the latest SEC disclosures | |
| About 83.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Financial Survey Liminatus Pharma Inhibikase Therapeutics |
- Analyzing Liminatus Pharma,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Liminatus Pharma,'s stock is overvalued or undervalued compared to its peers.
- Examining Liminatus Pharma,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Liminatus Pharma,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Liminatus Pharma,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Liminatus Pharma,'s stock. These opinions can provide insight into Liminatus Pharma,'s potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Liminatus Pharma, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Liminatus Pharma,. If investors know Liminatus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Liminatus Pharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.16) |
The market value of Liminatus Pharma, Class is measured differently than its book value, which is the value of Liminatus that is recorded on the company's balance sheet. Investors also form their own opinion of Liminatus Pharma,'s value that differs from its market value or its book value, called intrinsic value, which is Liminatus Pharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Liminatus Pharma,'s market value can be influenced by many factors that don't directly affect Liminatus Pharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Liminatus Pharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Liminatus Pharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Liminatus Pharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.